Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273214 | 1.00 | POLB (0.41) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL15388389 | 1.00 | POLB (0.41) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL6658887 | 0.87 | EPHX2 (0.50) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL245467 | 0.87 | — | — | |
| SCHEMBL22042675 | 0.86 | POLB (0.34) | POLBEPHX2MMP2MMP8EPHX1 | |
| SCHEMBL765446 | 0.86 | POLB (0.34) | POLBEPHX2MMP2MMP8EPHX1 | |
| Bicarbonate SCHEMBL10704742 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL11416981 | 0.84 | — | — | |
| SCHEMBL8959404 | 0.82 | EPHX2 (0.61) | EPHX2MMP2MMP8EPHX1NPC1 | |
| SCHEMBL10156594 | 0.82 | EPHX2 (0.61) | EPHX2MMP2MMP8EPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939334-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-03-26 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| EP-4204411-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-4157850-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2023-04-05 | — | — | EP | disclosed |
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| WO-2023018236-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2776432-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | P2K DYNAMICS INC. | 2013-11-21 | — | — | US | disclosed |
| US-8207349-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100113414-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7691888-B2 | Thiazolyl-dihydro-indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | CDK1, MAPK1, NFATC1 | POLB 2755/4885EPHX2 4402/4885MMP2 1683/4885 |
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | POLB 4158/4885EPHX2 1550/4885MMP2 1863/4885 |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | POLB 229/4885EPHX2 3796/4885MMP2 4183/4885 |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | POLB 1117/4885EPHX2 4666/4885MMP2 3909/4885 |
| US-11939334-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | POLB 176/4885EPHX2 2972/4885MMP2 3157/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | POLB 2786/4885EPHX2 4312/4885MMP2 3643/4885 |
| US-20100113414-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | MKI67, CYP11B1, IGF1R | POLB 4309/4885EPHX2 3479/4885MMP2 3858/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | POLB 874/4885EPHX2 3588/4885MMP2 3040/4885 |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | POLB 1117/4885EPHX2 4666/4885MMP2 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.